Most sexually transmitted infections are curable with the right antibiotics or antiparasitic drugs, but a handful of viral STIs remain in the body long-term once acquired. The dividing line is largely biological: bacteria and parasites can be killed by medication, while certain viruses weave themselves into your cells in ways that current medicine cannot fully reverse. That simple distinction, though, hides a lot of nuance worth understanding, from infections that are “incurable” yet nearly harmless to “curable” ones that are growing harder to treat every year.
The Curable Infections
Four of the most common STIs fall squarely into the curable category: chlamydia, gonorrhea, syphilis, and trichomoniasis. The first three are caused by bacteria, and trichomoniasis is caused by a single-celled parasite. In straightforward cases, a short course of antibiotics or antiparasitic medication eliminates the infection entirely. Chlamydia and gonorrhea often clear with a single dose or a brief regimen, syphilis responds to penicillin (a treatment that has worked for decades), and trichomoniasis is treated with oral drugs like metronidazole or tinidazole.1PubMed. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations
“Curable” does not mean “no big deal if you wait.” Chlamydia, for instance, often causes no symptoms at all, especially in women. Left untreated, it can silently infect the fallopian tubes and lead to tubal factor infertility, even without a recognized episode of pelvic inflammatory disease.2Medicine. Pelvic inflammatory disease Syphilis progresses through stages over years and can eventually damage the brain, heart, and other organs. The cure works, but it works best when the infection is caught early. Screening matters precisely because many of these infections stay quiet while doing damage.
Why “Curable” Is Getting Complicated
Gonorrhea deserves its own discussion because the bacterium behind it, Neisseria gonorrhoeae, has developed resistance to virtually every antibiotic ever thrown at it. Over the decades, treatment options have narrowed as the pathogen evolved, and resistance to ceftriaxone, the current last-line drug, has emerged.3PubMed Central. Neisseria gonorrhoeae Antimicrobial Resistance: The Future of Antibiotic Therapy Sporadic treatment failures have already been documented for throat infections, which tend to be harder to clear than genital ones.4PubMed Central. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge
This does not mean gonorrhea is about to become incurable for most people. Current combination regimens still work in the vast majority of cases. But the trend is heading in the wrong direction, and researchers have flagged the need for new drug classes and better surveillance to keep gonorrhea treatable.5PubMed Central. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future Similarly, trichomoniasis occasionally resists metronidazole, though most of those cases respond to tinidazole or higher-dose retreatment.1PubMed. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations The takeaway is that “curable” is a status that requires ongoing effort to maintain, not a permanent guarantee.
The Incurable Viral STIs
The STIs that cannot currently be eliminated from the body are all caused by viruses: HIV, herpes simplex virus (HSV-1 and HSV-2), hepatitis B, and human papillomavirus (HPV). Each behaves differently, but they share a common trick: they establish a long-term presence in your cells that the immune system struggles to root out completely.
HIV integrates its genetic material directly into the DNA of immune cells. A small fraction of those infected cells go dormant, producing no viral proteins and essentially hiding from both the immune system and antiviral drugs. This silent reservoir is the core reason HIV cannot be cured with current therapy.6PubMed Central. Can HIV Be Cured, and Should We Try? Herpes works through a similar principle of latency: after the initial infection, the virus retreats into nerve cells and periodically reactivates, causing outbreaks or invisible shedding. Herpesviruses have evolved an extensive set of mechanisms for dodging the immune system’s DNA-sensing pathways, which is one reason they are so persistent.7PubMed. Coevolution pays off: Herpesviruses have the license to escape the DNA sensing pathway
Hepatitis B can also integrate into host DNA in chronic infections, and those integrations sometimes occur near genes involved in cancer, which is part of the link between chronic hepatitis B and liver cancer.8Oncogene. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers Hepatitis B vaccines are highly effective at preventing infection in the first place, but once chronic infection is established, it is managed rather than cured.
HPV Is the Odd One Out
Human papillomavirus complicates the curable-versus-incurable framework because most HPV infections do eventually clear on their own. The immune system, through a process driven by T cells, resolves the majority of infections within a year or two.9PubMed Central. The immune response to papillomavirus during infection persistence and regression There is no antiviral pill that kills HPV; your body does the work, or it does not.
The trouble is when HPV persists. The virus has evolved ways to avoid triggering a strong immune response, and persistent infection with high-risk HPV types is the main driver of cervical cancer and several other cancers.10PubMed Central. The invisible enemy – how human papillomaviruses avoid recognition and clearance by the host immune system So HPV sits in a gray zone: it is “incurable” in the sense that no drug can eliminate it, but it is also not permanent in most people. For the minority with persistent infections, the consequences can be serious, which is why screening (like Pap tests and HPV tests) is so important for catching precancerous changes before they progress.
HPV vaccination has been remarkably effective at preventing infection with the virus types responsible for most HPV-related cancers and genital warts. Vaccine efficacy is highest in young people who have not yet been exposed to the virus, and real-world data show large drops in the targeted HPV types among vaccinated populations, with herd protection extending to unvaccinated people as well.11PubMed Central. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer12PubMed. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases Vaccination does not treat an existing infection, but it prevents new ones, which is the closest thing to a population-level cure for an incurable virus.
Living with Incurable STIs
“Incurable” sounds grim, but for several of these infections the reality of day-to-day life has changed dramatically thanks to modern treatment. The gap between “not curable” and “not manageable” is enormous.
HIV is the starkest example. Antiretroviral therapy suppresses the virus to undetectable levels in the blood, and at those levels transmission risk drops to essentially zero. A systematic review and meta-analysis found that among women on antiretroviral therapy whose viral load was below 50 copies per milliliter near the time of birth, perinatal transmission was about 0.2%, and in a subset of women who started therapy before conception and maintained suppression, there were zero transmissions.13The Lancet. Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis People on effective treatment now have near-normal life expectancies. The virus is still there, tucked away in its reservoir, but it is controlled to the point where it does not cause illness or spread to others.
Genital herpes, while far less dangerous, is also highly manageable. Daily antiviral therapy with valacyclovir prevented or delayed roughly 85% of recurrences that would have occurred without treatment, and after about four months of therapy, nearly 70% of patients remained outbreak-free compared to under 10% on placebo.14Sexually Transmitted Infections. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy Suppressive therapy also cuts viral shedding substantially, which reduces the risk of passing the virus to a partner. In one trial, the source partners taking valacyclovir shed HSV DNA on about 3% of days, compared with about 11% in the placebo group.15PubMed. Once-daily valacyclovir to reduce the risk of transmission of genital herpes Herpes outbreaks also tend to become less frequent and less severe on their own over time, independent of medication.
Diagnostic Challenges That Blur the Lines
One underappreciated wrinkle is that getting tested is not always straightforward. Herpes serology, for example, has a window period of up to 12 weeks after exposure. A negative blood test taken too soon after possible exposure does not rule out infection.16Clinical Infectious Diseases. Diagnosis and Management of Genital Herpes: Key Questions and Review of the Evidence for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines The virus can also be present in genital secretions without symptoms, meaning someone who has never had a noticeable outbreak can still transmit it. This is part of why herpes is so widespread: many carriers do not know they are infected.
For curable STIs, diagnosis is generally more reliable with modern nucleic acid testing, but there is still a gap between availability and use. Many people assume a standard checkup or even a general “STI panel” covers everything, when in fact trichomoniasis, herpes, and sometimes even syphilis are not included unless specifically requested. Knowing what you have been tested for, and what you have not, is half the battle.
Doxycycline After Exposure and Other Prevention Strategies
A newer strategy for preventing bacterial STIs that has generated significant attention is doxycycline post-exposure prophylaxis, or doxy-PEP. The idea is simple: taking a dose of the antibiotic doxycycline within 72 hours of a sexual encounter to prevent infection. Trials in men who have sex with men and transgender women have shown striking results. One major trial found that the combined incidence of gonorrhea, chlamydia, and syphilis was about two-thirds lower with doxy-PEP compared to standard care.17PubMed Central. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections
A subsequent randomized trial confirmed the finding, with bacterial STIs diagnosed at roughly 12% of quarterly visits in the doxy-PEP group versus about 31% in the standard-care group, an effect that persisted even after participants knew the treatment worked.18The Lancet Infectious Diseases. Doxycycline post-exposure prophylaxis for bacterial sexually transmitted infections: a randomised controlled trial and open-label extension A meta-analysis drilling into infection-specific effects found that doxy-PEP cut the risk of chlamydia by about 65% and syphilis by about 77%, but had no significant effect on gonorrhea.19Sexually Transmitted Infections. Efficacy of postexposure prophylaxis with doxycycline (Doxy-PEP) in reducing sexually transmitted infections: a systematic review and meta-analysis That gonorrhea gap is a reminder of the resistance problem discussed earlier: the same pathogen that has evolved past nearly every antibiotic class is not reliably stopped by doxycycline either.
There is legitimate concern that widespread doxycycline use could accelerate resistance, not just in gonorrhea but in other bacteria too. Balancing individual benefit against population-level resistance pressure is an active debate in public health. For now, guidelines in several countries recommend doxy-PEP specifically for populations at highest risk of repeated bacterial STIs, rather than as a blanket approach.
Research into Actual Cures for Viral STIs
The most tantalizing question for anyone living with an incurable STI is whether science is getting close to a real cure. The honest answer is that progress is real but a widely available cure remains distant for all viral STIs.
HIV cure research was galvanized by the case of the “Berlin patient,” a man with both HIV and acute myeloid leukemia who received a stem-cell transplant from a donor whose cells carried a mutation (CCR5-delta32) that blocks HIV’s main entry point into immune cells. He remained free of detectable virus for years after stopping antiretroviral therapy.20PubMed. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation A few additional patients have since achieved similar remissions through the same approach.21PubMed Central. Hematopoietic stem cell transplantation for HIV cure Stem-cell transplantation is too risky, too expensive, and too dependent on rare donor matches to be a scalable solution, but these cases proved that clearing HIV’s reservoir is biologically possible.
Gene-editing tools, particularly CRISPR-Cas systems, are being explored as a way to find and cut HIV DNA out of infected cells, targeting the latent reservoir that antiretroviral drugs cannot reach.22PubMed Central. A CRISPR-Cas Cure for HIV/AIDS Early-stage laboratory work has also applied CRISPR to herpesviruses, with some success in disrupting replicating HSV-1, though the approach was much less effective at targeting the virus during its latent, dormant phase.23PLOS Pathogens. CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections That latency obstacle is the core challenge: the same ability to hide quietly in cells that makes these viruses incurable also makes them hard targets for gene therapy. Reaching dormant viral DNA inside nerve cells or resting immune cells, without damaging the cells themselves, is a problem researchers have not yet solved for clinical use.
How the Vaginal Microbiome Fits In
An area of growing research interest is the relationship between the genital microbiome and STI susceptibility. The composition of vaginal bacteria appears to influence how likely a person is to acquire certain infections and how those infections behave once established. Vaginal microbiomes dominated by Lactobacillus species are associated with lower rates of STI acquisition, including chlamydia, while microbiomes with more diverse anaerobic bacteria are linked to a higher risk.24PubMed Central. Influence of cervicovaginal microbiota on Chlamydia trachomatis infection dynamics The mechanisms likely involve both direct antimicrobial effects from Lactobacillus-produced metabolites and more complex interactions with local immune defenses.25PubMed Central. The role of the genital microbiota in the acquisition and pathogenesis of sexually transmitted infections
This research is still in relatively early stages and has not yet translated into specific clinical interventions you can act on beyond general vaginal health practices. But it points toward a future where microbiome-based therapies or probiotics could become part of STI prevention, adding a layer of protection alongside condoms, vaccination, and prophylactic antibiotics.
The Stigma Problem
Whether an STI is curable or not, stigma remains one of the biggest obstacles to effective management. For HIV in particular, research shows that people who perceive or experience high levels of stigma have lower access to medical care and poorer adherence to antiretroviral therapy.26PubMed Central. Framing Mechanisms Linking HIV-Related Stigma, Adherence to Treatment, and Health Outcomes The effect is not just about skipping pills: people who anticipate stigmatizing reactions from others may avoid visiting clinics or pharmacies altogether, and the chronic stress of experienced stigma appears to worsen physical health markers independently of treatment adherence.
Herpes stigma operates differently but is similarly disproportionate to the actual health impact. Genital herpes is extremely common, typically causes mild or no symptoms, and is well controlled by medication. Yet the emotional burden of a diagnosis often dwarfs the medical reality, driven partly by outdated cultural associations and partly by the word “incurable” itself. One of the most useful reframings is recognizing that “incurable” and “serious” are not the same thing. A cold sore on the lip is caused by the same herpes virus family, and almost nobody treats that as a life-altering diagnosis.
For curable STIs, stigma can delay testing and treatment, allowing infections to spread and cause the very complications that make them dangerous. Chlamydia’s role in infertility, for example, is almost entirely a consequence of undetected and therefore untreated infection. Normalizing routine screening and open conversations with partners would do more to reduce harm from curable STIs than any new antibiotic could.
Partner Treatment and Reinfection
A practical challenge with curable STIs is that clearing the infection in one person does not help if their sexual partner is still infected. Reinfection rates for chlamydia and trichomoniasis remain stubbornly high, often in the range of 15 to 25% within months of treatment. One approach that public health programs have tried is expedited partner therapy, where the treated patient is given medication or a prescription to deliver to their partner without the partner needing to visit a clinic. While this is intuitively appealing, studies in adolescent populations have not shown a statistically significant reduction in reinfection rates with the approach, though the trend was in the right direction.27PubMed. Expedited Partner Therapy in Female Adolescents: A Study of Acceptance and the Impact on Reinfection Rates The challenge is partly logistical and partly behavioral: partners may not take the medication, or the person may have other untreated partners.
This is where the curable-versus-incurable distinction starts to feel less meaningful in practice. A curable STI that you keep catching again functions like a chronic condition. Addressing reinfection requires thinking beyond the individual and treating sexual networks, which is harder than prescribing an antibiotic but may be more impactful in the long run.